Additionally, survivin reduces the effectiveness of targeted therapies, such as Imatinib in chronic myeloid leukemia (CML) (Speletas et al., 2011; Carter et al., 2006) and Gefitinib in lung cancer (Zhou et al., 2018). Here, BIRC5 is linked to lung carcinoma.